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Background. Allocation of cadaver kidneys by 
graded human leukocyte antigen (HLA) compatibility 
scoring arguably has had little effect on overall sur-
vival while prejudicing the transplant candidacy of 
African-American and other hard to match popula-
tions. Consequently, matching has been proposed of 
deduced amino acid residues of the individual HLA 
molecules shared by cross-reactive antigen groups 
(CREGs). We have examined the circumstances under 
which compatibility with either method impacted 
graft survival. 
Methods. Using Cox proportional hazards regression 
modeling, we studied the relationship between levels 
of conventional lILA mismatch and other donor and 
recipient factors on primary cadaver kidney survival 
between 1981 and 1995 at the University of Pittsburgh 
(n=I,780) and in the United Network for Organ Shar-
ing (UNOS) Scientific Registry during 1991-1995 
(n=31,291). The results were compared with those ob-
tained by the matching of amino acid residues that 
identified CREG-compatible cases with as many as 
four (but not five and six) lILA mismatches. 
Results. With more than one lILA mismatch (>85% of 
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patients in both series), most of the survival advantage 
of a zero mismatch was lost. None of the lILA loci were 
"weak." In the UNOS (but not Pittsburgh) category of 
one-lILA mismatch (n=1334), a subgroup of CREG-
matched recipients (35.3%) had better graft survival 
than the remaining 64.7%, who were CREG-mis-
matched. There was no advantage of a CREG match in 
the two- to four-HLA incompatibility tiers. Better graft 
survival with tacrolimus was observed in both the 
Pittsburgh and UNOS series. 
ConcluBions. Obligatory national sharing of cadaver 
kidneys is justifiable only for zero-lILA-mismatched 
kidneys. The potential value of CREG matching ob-
served in the one-HLA-mismatched recipients of the 
UNOS (but not the Pittsburgh) experience deserves 
further study. 
The use of human leukocyte antigen (HLA*) matching as 
the dominant factor for the allocation of cadaver kidneys has 
been criticized on grounds that it is poorly predictive of graft 
survival except when perfect and diverts the organs away 
from African-American and other hard to match recipients 
(1-5). Before undertaking refonns in organ distribution, it is 
necessary to have precise knowledge about the extent to 
which degrees of HLA matching influence prognosis. Thus, 
the primary aim of the present study was to examine the 
effect of prospective HLA matching on primary cadaver graft 
survival in patients compiled in the United Network for 
Organ Sharing (UNOS) database for the years 1991-1995 
* Abbreviations: CI. confidence interval; CREG. cross-reactive an-
tigen group; HLA. human leukocyte antigen; HR. hazard ratio; 
UNOS, United Network for Organ Sharing. 
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and in a separate 15-year (1981-1995) longitudinal study at 
the University of Pittsburgh. A secondary objective was to 
explore whether cross-reactive antigen group (CREG) match-
ing, which is a refinement of conventional histocompatibility 
determination (6-10), might offer a better chance of allograft 
survival to a broader range of recipients. 
PATIENTS AND METHODS 
Study subjects. A total of 2723 patients underwent kidney trans-
plantation at the University of Pittsburgh between 1981 and 1995 
and had complete follow-up to the end of 1996. Of that group of 
patients, 1897 received primary cadaveric allografts under immune 
suppression based on cyclosporine (n= 1217), tacrolimus (n=649), or 
azathioprine (n=31). Patients treated with azathioprine as the base-
line immunosuppressant were excluded from analysis, as well as 86 
patients in whom none of the HLA antigens were identified ("double 
blanks") at one or more of the A, B, or DR loci, in either the donor or 
the recipient. Therefore, the analyses were based upon survival of 
1780 allografts, 1142 under cyc1osporine and 638 under tacrolimus. 
The HLA and other data collected in these cases were compared 
with those from 31,291 primary cadaver transplantations reported 
from 243 centers to the UNOS Scientific Renal Transplant Registry 
during the period from 1991 through 1995. Donor and recipient 
serologic typing of the HLA-A, -B, and -DR loci was routinely ob-
tained throughout the period of both studies. All "splits" (11) were 
reviewed individually and categorized appropriately. The degree of 
incompatibility was expressed in each case as zero to six HLA mis-
matches. It has been reported (12) and was confirmed in this study 
(data not shown) that such results accurately reflect the compatibil-
ity expressed by the six- to zero-HLA match scale. To achieve statis-
tical independence between the two study cohorts, all Pittsburgh 
patients reported to the registry were excluded from the UNOS 
analysis. 
Kidney allocation. From the beginning of the 15-year Pittsburgh 
study, six-antigen-matched allografts were targeted selectively to 
cadaver kidney recipients. This restricted use of HLA matching was 
the centerpiece of the computerized "point system" introduced in 
western Pennsylvania in 1986 for the equitable allocation of cadaver 
kidneys (13). Although credit was given to lesser degrees of matching 
and to logistic and urgency of need factors, time waiting on dialysis 
was shown in extensive field trials during 1986-1987 to be the single 
most important determinant for organ allocation in the vast majority 
of cases (13). The Pittsburgh point system was adopted by UNOS for 
nationwide use beginning in November 1987, but variances at local, 
regional, and national levels had subordinated all other allocation 
credits (including waiting time) to gradations of HLA matching by 
the time of the 1991-1995 UNOS case accrual. During this period, A 
locus matching was deemphasized by UNOS directive (4). 
CREGs. Although the genes at the HLA-A, -B, and -DR loci are 
highly polymorphic (greater than 250 known specificities), their re-
spective class I and II protein products have minimal sequence 
variability over a range of single and regional amino acid residue 
positions. Because these different residues share antigenic determi-
nants. they constitute a basis for common 1 public) groups (also called 
CREGs) (15) against which anti-HLA antibodies are largely directed 
(16). The inference is that donor-recipient compatibility might be 
achieved by avoiding donor mismatches of these residues rather than 
of the complete HLA molecules. A computer program 1 kindly pro-
vided by Dr. Steve Takemoto 1911 was therefore used to convert 
conventional donor and recipient HLA phenotypes in both the Pitts-
burgh and UNOS data to 10 groups of amino acid residues repre-
senting class I public determmants and 10 broadly defined class II 
antigens 19). The presence of any residuels) in the donor but not in 
the recipient was by definition a CREG mismatch. 
Statistical analysis. The relationship between the level of HLA 
mismatch and rate of graft survival was assessed with Cox propor-
tional hazards regression modeling 1 program lL of the BMDP pack-
age [17]), which takes into account varying lengths of patient follow-
up. Regression modeling was also used in the secondary analysis of 
the relationship between CREG match and graft survival at various 
levels of HLA incompatibility. The results were summarized as ad-
justed hazard ratios (HRs) with corresponding 95% confidence inter-
vals. The estimated HR (or relative hazard) is a measure of associ-
ation that can be interpreted as a relative risk. 
The analysis strategy consisted of initially fitting a model with only 
the level of HLA mismatch. This yielded unadjusted HRs, estimating 
the relative risk of individual one- to six-HLA mismatches versus zero 
mismatches. Adjusted HRs were obtained subsequently by modeling all 
the variables simultaneously. A final "parsimonious" model was arrived 
at by eliminating all nonconfounders from the previous model using a 
backward selection approach. The "change-in-estimate" criterion was 
used to measure the level of confounding among the factors in the model 
(18). A factor was considered to be a confounder if it produced more than 
a 10% change in any of the HLA-related HRs of interest. The resulting 
model contained the HLA factor in addition to all possible confounders 
detected according to this criterion. 
An assumption underlying the Cox regression analysis is that the 
hazard rates are proportional. This assumption was examined by 
plotting the graft survival curves on a log-log scale. Because the 
curves were parallel, the proportional hazards modeling approach 
was regarded as appropriate. Although a model-free approach could 
have been used, the number of subcategories over which the data 
would have been dispersed would have yielded imprecise estimates 
of graft survival rates. Regression modeling is desirable because it 
preserves precision while simultaneously controlling for many po-
tentially confounding factors, as well as allowing for the efficient 
detection of statistical interactions. 
Differences between levels of HLA mismatch were tested for sta-
tistical significance using a likelihood ratio test (17). Graft survival 
rates and half-lives (beyond 1 year) were estimated from the regres-
sion model. The half-life values were estimated according to the 
formula HL=210g.2100g"sI_log"s2)' where 8 1 and 8 2 are the pre-
dicted survival rates from the regression model at 1 and 3 years, 
respectively. Adjusted graft survival curves were obtained from the 
regression model by using the mean value for the covariate being 
adjusted (19). Because half-lives customarily have been calculated 
taking into account only actual data from 1 year onward (20), this 
conventional method was also used for the primary UNOS analysis 
with side-by-side presentation of the latter results in parentheses 
(Fig. 1). Because the results were undistinguishable statistically 
from those with the Cox regression methodology, the conventional 
half-life analyses will not be discussed further. 
Missing covariate data were replaced with mode values for cate-
gorical variables and median values for continuous variables. Less 
than 2% of values were missing for any covariate in the Pittsburgh 
data, except for duration of cold ischemia (30% missing) and body 
mass index (42% missing). Collection of data on these two covariates 
was not started until January 1986 and January 1987, respectively. 
In UNOS, less than 5% of values were missing for any covariate. The 
effect of the imputation procedure was assessed by comparing mod-
els fit with imputed values to models in which patients with missing 
data were excluded. None of the analyses yielded appreciably differ-
ent results. All continuous variables were categorized to obviate 
linearity assumptions using categories suggested previously in the 
kidney transplant literature 121. 22), 
RESULTS 
Donor and Recipient Characteristics 
The University of Pittsburgh and UNOS registry cases 
were similar across all but two factors (Table ll. The first 
exception was a cold ischemia time that was nearly 10 hr 
longer in the Pittsburgh data, exceeding 36 hr for 26'k of the 
allografts. Second. 96.8'k of recipients in the UNOS registrv 
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FIG. 1. Comparisons of predicted graft survival curves (top panels) 
and HRs (bottom panels) by numbers of HLA -A, -B, -DR-mis-
matched primary cadaver renal transplantations reported to the 
UNOS (left panels) and University of Pittsburgh (right panels) da-
tabases. The estimates of rates of graft survival (8), half-lives (HL) 
beyond 1 year after transplantation, and HRs were computed for 
each degree ofHLA mismatch (one to six antigens) after adjusting for 
the potential confounding effects of the regimen of immune suppres-
sion (i.e., cyclosporine vs. tacrolimus>. The HL in parentheses for the 
UNOS cases was computed with the most widely used formula (see 
Patients and Methods). The differences in HRs (95% confidence lim-
its given by darkened error bars shown in the bottom panels) be-
tween HLA groups and the one-antigen-mismatched group were 
significant when indicated by P-value (listed above arrow line de-
picting comparison). 
were treated with cyclosporine compared with 64.2% in Pitts-
burgh, where cyclosporine was largely replaced by tacrolimus 
from November 1989 onward (23). Although dependence on 
prednisone was much reduced in the tacrolimus cohort (23, 
24), the principles of management were the same as had been 
delineated previously with cyclosporine (25). 
Primary Analysis 
Pittsburgh series. Of the 1780 Pittsburgh recipients un-
dergoing primary cadaver kidney transplantation between 
1981 and 1995, 936 experienced graft failure. The median 
time to failure or end of study {December 1996) was 3.83 
years among all patients. For the 936 who experienced graft 
failure, the median time to failure was 1.83 years. The ad-
justed HRs measuring the effect ofHLA mismatching and all 
other factors on the (relative) risk of graft failure arising from 
the proportional hazards regression models are shown in 
Table 2. 
Although other factors influenced graft survival signifi-
cantly (e.g., type of immune suppression. donor and recipient 
age, recipient race, insulin-dependent diabetes. and peak 
panel-reactive antibody), none of the corresponding HRs 
reached the magnitudes attained for the full range of HLA 
matching. Inasmuch as the regimen of immune suppression 
i i.e., cyclosporine vs. tacrolimus) was identified. on the basis 
of the change-in-estimate criterion. to be the only confounder 
for measuring the HLA eifect. this factor alone was retained 
TABLE 1. Baseline characteristics of kidney transplant recipients 
and donorsa 
Factors Pittsburgh 1981-1995 UNOS 1991-1995 (n=1780) (n=31291) 
Recipient factors 
Age (years) 
Mean", SO 41.8 '" 15.1 44.0 :!: 14.0 
0-17 5.8 3.7 
18-39 39.4 32.7 
40-54 31.5 38.7 
55+ 23.3 24.9 
Gender 
Female 37.5 39.9 
Male 62.5 61.1 
Race 
Caucasian 78.9 59.0 
African-American 14.7 25.9 
Other 6.4 15.1 
BMIQ (kglm2 ) 
Mean", SO 23.9:!: 4.2 24.7 :!: 5.2 
0-20 12.2 19.7 
21-30 81.1 68.0 
31+ 6.7 12.3 
Diabetes 
No 77.6 79.3 
Yes 22.4 20.7 
Peak PRA" (%) 
Mean", SO 15.5 :!: 25.0 12.2 :!: 22.1 
0 23.1 35.0 
1-10 45.6 38.8 
11-50 20.2 18.5 
51+ 11.1 7.7 
Immunosuppression 
Cyclosporine 64.2 96.8 
Tacrolimus 35.8 3.2 
Donor factors 
Age (years) 
Mean:!: SD 27.9 :!: 18.0 32.9 :!: 17.0 
0-17 30.3 21.6 
18-39 43.1 41.8 
40-54 16.3 23.9 
55+ 10.3 12.8 
Gender 
Female 36.3 38.4 
Male 63.7 61.6 
Race 
Caucasian 90.9 78.7 
Mrican-American 6.3 11.1 
Other 2.8 10.3 
Cold ischemia time (hr) 
Mean:!: SO 32.2 :!: 9.1 22.8 :!: 9.6 
0-23 14.8 57.6 
24-35 59.2 32.8 
36-47 18.4 8.0 
48+ 7.6 1.6 
Transplant factors 
ABO compatibility 
Nonidentical 3.0 5.1 
Identical 97.0 94.9 
HLA-ABOR mismatches 
Mean", SO 3.6 :!: 1.4 3.3 :!: 1.5 
0 3.3 7.9 
3.7 4.3 
2 11.0 12.8 
3 25.6 25.8 
4 29.3 27.3 
5 20.5 16.6 
6 6.6 5.4 
Transplantatton era 
Before 1988 47.7 0.0 
January 1. 1988 onward 52.3 100.0 
" BM!, body mass index: PRA, panel-reactive antibody. 
in the final Pittsburgh regression model. The HRs in this 
final model (Table 3) were within 10% of the HR adjusted for 
all covariates I Table 2>. 
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TABLE 2. Adjusted HRs from Cox proportional hazards regression analyses 
Baseline factors 
HLA-A,B,DR mismatches 
1 vs. 0 
2 vs. 0 
3 VS. 0 
4 VS. 0 
5 VS. 0 
6 VS. 0 
Immunosuppressive therapy 
Tacrolimus VS. cyciosporine 
Recipient age (years) 
0-17 VS. 18-39 
40-54 VS. 18-39 
55+ vs. 18-39 
Recipient gender 
Male VS. female 
Recipient race 
African-American VS. Caucasian 
Other VS. Caucasian 
Recipient BMI (kg/m2) 
21-30 VS. 0-20 
31+ VS. 0-20 
Recipient diabetes status 
Yes VS. no 
Recipient peak PRA (%) 
1-10 VS. 0 
11-50 VS. 0 
51+ VS. 0 
Donor age (years) 
0-17 VS. 18-39 
40-54 VS. 18-39 
55+ VS. 18-39 
Donor gender 
Male VS. female 
Donor race 
African-American VS. Caucasian 
Other VS. Caucasian 
Cold ischemia time (hr) 
24-35 VS. 0-23 
36-47 VS. 0-23 
48+ VS. 0-23 
ABO compatibility 
Identical VS. nonidentical 
Transplant era 
1988 onward vs. before 1988 
a Abbreviations are as defined in Table 1. 
Adjusted graft survival curves and HRs are shown in Fig-
ure 1. Graft survival was inversely related to the degree of 
HLA mismatching lP<0.001). with a 3-year survival differ-
ence of 83% and 64% in recipients of zero- and six-HLA-
mismatched kidneys. respectively. Between these extremes. 
however, there was only a 3% difference in survival in the 
recipients of two- to five-HLA mismatches. who made up 
86.4% of all Pittsburgh cases. Within this spectrum. HRs rose 
from 1.92 to only 2.16 and half-lives were 9-10 years. The 
HRs measuring the risk of mismatch at the A and B loci 
(class Il were identical and exceeded the risk of mismatch at 
the DR locus (class II) (Table 4>. Of particular interest. a 
second incompatibility at either the A. B. or DR locus did not 
increase the survival penalty imposed by a first one in two of 
these three loci. 
Pittsburgh 1981-1995 
(n=1780) 
HR(95% cn 
1.04 (0.50-2.17) 
1.85 (1.00-3.42) 
2.08 (1.15-3.75) 
2.06 (1.14-3.71) 
2.08 (1.15-3.78) 
2.38 E1KO~K44F 
0.67 (0.54-0.84) 
1.41 (1.04-1.91) 
1.06 (0.91-1.24) 
1.25 (1.05-1.49) 
1.17 (1.02-1.35) 
1.35 (1.13-1.61) 
0.57 EMK4~KTUF 
1.03 (0.80-1.32) 
1.33 (0.94-1.89) 
1.23 (1.06-1.44) 
0.93 (0.78-1.11) 
1.03 (0.85-1.25) 
1.43 (1.14-1.79) 
1.08 (0.93-1.27) 
1.34 (1.10-1.63) 
1.75 (1.37-2.24) 
1.03 (0.90-1.19) 
1.24 (0.95-1.63) 
1.50 (0.97-2.32) 
0.96 (0.78-1.17) 
1.10 (0.86-1.41) 
1.23 (0.92-1.65) 
1.32 (0.87-2.01) 
0.77 (0.63-0.95) 
UNOS 1991-1995 
(n=31291) 
HR(95% CIl 
1.22 (1.04-1.43) 
1.28 U.12-1.44) 
1.31 (1.17-1.47) 
1.46 (1.30-1.63) 
1.49 (1.32-1.68) 
1.60 (1.39-1.85) 
0.70 (0.60-0.83) 
1.17 (1.02-1.34) 
0.95 (0.89-1.00) 
1.12 (1.05-1.19) 
1.04 (0.98-1.09) 
1.28 (1.21-1.35) 
0.86 (0.79-0.92) 
1.05 (0.98-1.12) 
1.17 (1.07-1.27) 
1.19 (1.12-1.26) 
1.00 (0.95-1.06) 
1.09 (1.02-1.16) 
1.31 (1.20-1.43) 
1.21 (1.13-1.29) 
1.41 (1.33-1.50) 
1.91 (1.78-2.04) 
0.92 (0.88-0.97) 
1.18 (1.10-1.27) 
1.06 (0.98-1.15) 
1.08 (1.02-1.13) 
1.17 (1.08-1.28) 
1.15 (0.97-1.36) 
0.96 (0.86-1.08) 
Not applicable 
Because HLA typing methods and reagents had improved 
with time and because immune suppression was different in 
the later period of this study, the cyclosporine- and tacroli-
mus-defined cohorts were examined in two further analyses. 
First. a test for interaction between the level of HLA mis-
match and the type of immunosuppression on graft survival 
was performed using a regression analysis. The test statistic 
yielded a nonsignificant result (P=0.81). indicating that the 
relationship between HLA matching and graft survival could 
not be considered different under the two types of therapy. 
For completeness. maximum likelihood estimates of A. B. 
and DR loci antigen and gene frequencies were computed for 
all 1780 Pittsburgh patients. These estimates also were com-
puted for the 896 and 508 Caucasian recipients treated with 
cyclosporine and tacrolimus. respectively. and separately for 
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TABLE 3. Adjusted HRs from final Cox proportional hazards regression analyses 
Baseline factors 
Pittsburgh 1981-1995 (n= 1.780) UNOS 1991-1995 (n=31.291) 
HR (95% Cll 
HLA-A.B,DR mismatches 
1 vs. 0 1.08 (0.52-2.24) 
2 vs. 0 1.92 (1.05-3.51) 
3 VS. 0 2.17 (1.21-3.89) 
4 VS. 0 2.13 (1.19-3.80) 
5 VB. 0 2.16 (1.20-3.88) 
6 vs. 0 2.44 (1.32-4.51) 
Immunosuppressive therapy 
TacrolimuB VS. cyciosporine 0.66 (0.55-0.78) 
TABLE 4. Percentage of individual HLA-A, -B, and -DR loci 
mismatches at baseline, and adjusted HRs from Cox regression 
UNOS Pittsburgh UNOS 1991-1995 Pittsburgh 1981-
(n=31,2911 (n=1.7S0) HR(95% CIl 1995 HR (95% CIl 
HLA-A 
0 17.2 15.5 1.00 1.00 
1 VS. 0 41.2 44.9 1.19 (1.10-1.27) 1.51 (1.23-1.85) 
2 vs. 0 41.6 39.6 1.26 (1.17-1.35) 1.39 (1.13-1.71) 
HLA-B 
0 17.0 lOA 1.00 1.00 
1 vs. 0 43.8 43.0 1.17 (1.09-1.26) 1.51 (1.14--1.99) 
2 VB. 0 39.2 46.5 1.29 (1.20-1.39) 1.61 (1.22-2.13) 
HLA-DR 
0 32.6 22.7 1.00 1.00 
1 VB. 0 49.7 52.6 1.16 (1.09-1.22) 1.26 (1.06-1.50) 
2 VB. 0 17.7 24.7 1.27 (1.19-1.36) 1.18 (0.97-1.45) 
the 1060 and 545 Caucasian donors in the two treatment 
cohorts. The analyses indicated that, for both recipients and 
donors, the Pittsburgh HLA-A, -B, and -DR antigen and gene 
frequencies were indistinguishable (within 1 standard error) 
from those reported in the UNOS Scientific Renal Registry, 
and between drug cohorts. These additional analyses indi-
cated that the HLA types observed in the Pittsburgh patients 
were expressed consistently and are generally representative 
of the transplant population. 
UNOS database. Based on complete follow-up data for 
31,291 UNOS transplantations between 1991 and 1995, 
6,960 (22.2%) grafts failed after a median time to failure of 
0.37 years. Among all patients, the median time to failure or 
end of study (December 1996) was 1.60 years. Differences in 
median times between Pittsburgh and UNOS transplanta-
P HR (95% Cll P 
0.83 1.22 (1.04--1.43) 0.013 
0.035 1.26 (1.12-1.43) <0.001 
0.009 1.33 (1.19-1.49) <0.001 
0.011 1.50 (1.34--1.67) <0.001 
0.010 1.54 (1.37-1.73) <0.001 
0.004 1.64 (1.43-1.89) <0.001 
<0.001 0.75 (0.64-0.88) 0.001 
tions reflect differences in follow-up periods and not differ-
ences in overall graft survival (see comparative rates in Fig. 
n The results of the adjusted analysis for the full model are 
shown in Table 2, and the final model in Table 3. Although 
immune suppression was not identified as a confounder for 
the UNOS data, the final model nevertheless included this 
factor to ensure comparability between the two study co-
horts. Note that the 95% confidence intervals about the HRs 
for the UNOS data are almost always enclosed within the 
corresponding interval estimates for the Pittsburgh data. 
As in the Pittsburgh series, graft survival was related 
inversely to the extent ofHLA mismatch (P<O.OOI) but with 
a more graded effect from the predicted 80% 3-year survival 
with zero mismatches to 69% with six-antigen mismatches 
(Fig. 1). Within the two- to five-HLA-mismatch spectrum 
that encompassed 82.5% of the recipients, HR rose modestly 
from 1.26 to 1.54 and 3-year survival was clustered within a 
range of 5%. Post-I-year half-lives were bracketed at 9-11 
years with Cox regression analysis and 9-10 years with 
conventional half-life calculations, respectively (Fig. n 
Separate analysis showed that the negative effects of mis-
matching at the A, B, and DR loci were essentially the same 
at each locus (Table 4). Unlike the analysis of Pittsburgh 
data, a double incompatibility added to the HR imposed by 
the first one. 
Secondary Analysis 
In the UNOS collection, the percentage of CREG matches 
dwindled rapidly with each further HLA mismatch, from 
tiers 1 (35.3%) to 4 <0.7%). No CREG matches were identified 
in tiers 5 and 6. The same pattern was seen in the Pittsburgh 
series (Table 5). 
TABLE 5. Percentage of 0 CREGs at each level of 1-4 ABDR mismatch, and adjusted hazard ratios from Cox regression 
UNOS 1991-95 
1 (n=1.334) 2 (n=4.00S) 3 (n=8.071) 4 (n=8.542) 2-4 (n=20.621) 
Percentage of 0 CREG (n) 35.3 (471) 10.4 (416) 2.5 (206) 0.7 (57) 3.3 (679) 
HR (95'7c CIl 
o CREG vs. 0 ABDR 1.02 <0.80-1.30> 1.34 (1.07-1.69) 1.36 <0.99-1.85) 1.15 (0.61-2.16) 1.33 (1.11-1.62) 
1 + CREG vs. 0 ABDR 1.33 (1.11-1.58) 1.260.11-1.42) 1.33 (1.19-1.49) 1.50 (1.34--1.68) 1.39 (1.25-1.54) 
Pittsburgh 1981-95 
1 (n=65) 2 (n=196) 3 (n=456) 4 (n=522) 2-4 (n=I.174) 
Percentage of 0 CREG (n) 27.7 (18) 6.6 (13) 0.9 (4) 0.6(3) 1.7(20) 
HR (95,} eI) 
o CREG VS. 0 ABDR 1.30 <0.49-3.46) ~ot estimated ~ot estimated ~ot estimated 1.96 <0.80-4.80) 
I.,. CREG VS. 0 ABDR 1.01 <0.46-2.21) ~ot estimated ~ot estimated ~ot estimated 2.11 (1.19-3.75) 
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FIGURE 2. Adjusted graft survival curves (top panels) and HRs (bot-
tom panels) from a secondary analysis of the UNOS (left panels) and 
Pittsburgh (right panels) databases that bifurcated each degree 
(1-4) of HLA-A, -B, -DR-mismatched transplants by the presence 
(1 +res) or absence (Ores) of a CREG mismatch. The differences in 
HRs (95% confidence limits given by darkened error bars shown in 
the bottom panels) between CREG-HLA groups and the Ores-one-
HLA antigen-mismatched group were significant when indicated by 
P-value (listed above arrow line depicting comparison). 
Using the zero-HLA mismatch results as the reference 
category (HR 1.0), only the CREG-matched allografts ex-
tracted from the UNOS one-HLA-mismatch collection had 
comparable graft survival (HR= 1.02, 95% confidence inter-
val [Cl]: 0.80-1.30) (Table 5). The companion CREG-mis-
matched kidneys at this one-HLA-mismatch level had an HR 
of 1.33 (95% CI: 1.11-1.58). Paradoxically, in the small Pitts-
burgh series, the CREG-mismatched kidneys had better sur-
vival (HR 1.01) than those that were matched (HR 1.30) (Fig. 
2). There was no benefit in either the UNOS or Pittsburgh 
analysis of a CREG match at the two- to four-HLA mismatch 
level (Table 5). These findings also are shown in Figure 2, 
expressed in terms of graft survival. For clarity in presenting 
the survival curves, HLA mismatch categories 2-4 shown 
individually in Table 5 were combined for Figure 2 inasmuch 
as there were no discernible differences among the HRs nor 
among the graft survival rates. The aggregation of categories 
also allowed the Pittsburgh CREG data, which consists of 
fewer numbers. to be analyzed alongside the UNOS data. 
Exploratory Analysis 
The problems of organ allocation by tissue matching in an 
ethnically pluralistic society were evident in our HLA anal-
ysis of the 31.291 UNOS cases. Of the 2.460 zero-HLA-mis-
matched kidneys used during 1991-1995, only 174 were 
transplanted into the 8111 African-American recipients. for a 
rate of2.1%. The other 2.286 went to the 23.180 "all others," 
for a rate of 9.9%. 
,\llocation of the 1334 one-HLA-mismatched kidneys was 
also unequal: 206 went to the 8.111 African-Americans (2.5% 
Black Recipients Non-Black Recipients 
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FIGURE 3. Adjusted graft survival curves (top panels) and HRs (bot-
tom panels) from an exploratory analysis of the UNOS database 
stratifying CREG histocompatibility by recipient race (black vs. non-
black). Darkened error bars (shown in the bottom panels) represent 
95% confidence limits for HRs. using zero mismatch as the reference. 
Note that no formal tests of significance were conducted due to the 
exploratory nature of the analysis. 
rate) versus 1,128 to the 23,180 all others (4.9%). Because 
this was the only HLA mismatch tier within which there was 
any evidence of a CREG match benefit (see previous section), 
we determined the ethnic allocation rates of the CREG-
matched and -mismatched organs within the one-HLA cate-
gory. Of the 206 given to African-Americans, 81 (39.3%) were 
CREG-matched compared with 390/1,128 (34.6%) trans-
planted to the "all other" population. 
Although under-represented overall in the one-HLA mis-
match tier, the 81 African-Americans in this category with a 
CREG match were estimated to have better graft survival 
than the 125 with a CREG mismatch, far exceeding the 
advantage of a CREG match in the "all other" population 
(Fig. 3), Incongruously, survival of the CREG-matched one-
HLA-mismatched kidneys in African-Americans exceeded 
that of zero-HLA-mismatched kidneys (Fig. 3), which by def-
inition also were CREG-matched. 
For easier comparison of graft survival in the African-
American and non-African-American populations of the one-
HLA mismatch category, the HRs in Figure 3 were converted 
to relative risks using the CREG match results as the refer-
ence (i.e., 1.5/0.7=2.14 for African-Americans; 1.211.1=1.09 
for non-African-Americans). With this calculation, the 125 
African-American patients with a one-HLA mismatch who 
were CREG-mismatched were 2.14 times (95% CI: 1.11-4.10) 
more likely to fail than the 81 with a CREG match. In 
contrast. the concurrent non-African-American relative risk 
was only 1.09 (95% CI: 0.88-1.58). 
It is important to emphasize. first. that the number of 
cases in the foregoing exploratory analysis of CREG match-
f 
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ing in the one-HLA match tier was small and, second, that a 
CREG match appeared to have no advantage for either race 
in the two- to four-HLA mismatch groups (Table 5 and Fig. 
3). 
DISCUSSION 
Except for the prevention of hyperacute rejection by obser-
vance of ABO compatibility guidelines (26) and the routine 
use of the cytotoxic cross-match (27), immunologic screening 
has had a limited impact on survival after cadaver kidney 
transplantation. The failure of prospective HLA matching to 
upgrade overall graft survival documented in the report by 
Held et al. (28) from the United States Renal Data System 
was in stark contrast to the historically rooted conviction 
that matching would be the most important means of up grad-
ing organ transplant outcome (see Brent [29]). It also was 
inconsistent with experience in clinical bone marrow trans-
plantation, where incompatibility of even one or two HLA 
alleles was associated with nearly universal failure (30-32) 
until the 1990s. Instead, the benefit of graded HLA matching 
for kidney transplantation has been more subtle, frequently 
not obvious in single-center studies, and most convincingly 
displayed in registry compilations (29, 33). 
Ultimately, a generic explanation for the disparity between 
bone marrow and organ transplantation was suggested by 
the discovery that passenger leukocytes including pluripo-
tent stem cells migrate after kidney and other organ trans-
plantation and result in persistent multilineage chimerism 
(34, 35). Variable induction of mutual nonreactivity by the 
genetically disparate leukocyte populations, each obeying its 
own genetic program, would obscure the expected histocom-
patibility influence unless the recipient is immunologically 
defenseless: i.e., in the neonatal tolerance model, recipient 
cytoablation in all species, or as the consequence of breeding 
(e.g., the F 1 hybrid preparations) (36). 
In addition, experimental (37) and epidemiologic evidence 
(38, 39) suggests that much of the late allograft attrition is 
due to the non-HLA factors that were evident in the present 
study (see Table 2) and elsewhere (40). These factors help 
explain why the average time to loss of 50% of cadaver 
kidneys still functioning at 1 year (the "half-life") has been 
fixed until recently at 8-10 years (4]) except when there is a 
zero-HLA mismatch. as confirmed in our current analyses. 
HLA matching in organ transplantation was first tested 
retrospectively (42) and prospectively (43) in live donor kid-
ney recipients treated with azathioprine and prednisone, 
with or without adjunct antilymphocyte globulin. As had 
been predicted, HLA-matched allografts had the best sur-
vival and function, least dependence on maintenance pred-
nisone, and fewest histopathologic abnormalities in routine 
2-year postoperative biopsies (44). The results of these stud-
ies were generally consistent with those from the classical 
skin graft investigations in nonimmunosuppressed healthy 
volunteers by Rapaport and Dausset (45-47) upon which the 
"laws of HLA" are based. Unexpectedly, however. a cumula-
tive adverse effect of mismatching in the kidney recipients 
could not be identified. When similar observations were 
made in live donor recipients during the cyclosporine era (48, 
49), it was concluded that the lower survival of contempora-
neously transplanted cadaveric kidneys commonly attributed 
to generally inferior HLA compatibility was due largely to 
premortem and preservation damage. 
The equally imprecise prognostic discrimination of HLA 
matching in cadaver kidney transplant cases, first recog-
nized by Mickey and Terasaki et al. (50), was evident in the 
current analyses. Given the large sample sizes in both the 
single-center and UNOS databases, virtually every compar-
ison of the different levels of mismatching showed statistical 
significance. These observations confirm the scientific valid-
ity of the matching technology and the continuing need for 
first-class histocompatibility laboratories. However, as Held 
et al. (28) have demonstrated, the important clinical issues 
are the magnitude of the observed differences and the num-
bers of patients in the HLA-defined groups. The absence of a 
large or consistent matching effect except at the top was 
noteworthy. In both the Pittsburgh and UNOS series, ap-
proximately 85% of the cases were in the two- to five-HLA 
mismatch spectrum where I-year survival was clustered 
within 3%, with half-life projections thereafter in the narrow 
spread of 9-11 years. 
In Pittsburgh, access to the national donor pool beginning 
in January 1988 resulted in a reduction of average mis-
matches from 4.0 to 3.3, but only 2.0% of recipients were 
moved out of the two- to five-HLA incompatibility range 
within which matching has little benefit. A second manage-
ment change, the preferential use of tacrolimus-based im-
mune suppression after 1989 (23,24), was associated with an 
increased early and late graft survival. If the 15-year expe-
rience had been simply pooled as in many registry reports 
(33), the better survival in the later period would have been 
attributed erroneously to the lower average number of mis-
matches under tacrolimus therapy, whereas the poorer ear-
lier results would have been ascribed to the more frequent 
use of mismatched allografts under cyclosporine. To control 
for the potential confounding effect of drug therapy, graft 
survival was adjusted for the treatment factor in the regres-
sion analyses, which showed that the relationship between 
survival and match was similar with both immunosuppres-
sive regimens. 
The findings reported herein should be considered in re-
forming cadaver kidney allocation. It is an established fact 
that the absence of HLA mismatches improves short- and 
long-term cadaver kidney allograft survival (21,28,39) and 
that there is no weak locus (i.e., A locus) that can be mini-
mized in importance as is current UNOS policy (14). Such 
highly compatible organs were found until recently for less 
than 5% of cadaver renal transplant recipients in the United 
States (28). The incidence rose to 7.9% in the 1991-1995 
UNOS experience, but with the ethnic bias that was also seen 
with one-HLA-mismatched kidneys. 
Presumably, the prospects for the African-American can-
didates could be improved by efforts, such as those that 
Callender et al. (51) have described, to recruit donor partic-
ipation by minorities. The combination of increased minority 
donation and national sharing theoretically could result in 
zero-mismatched allografts for approximately 20% of candi-
dates (52). Despite the inherent inequity of obligatory na-
tional sharing of zero-mismatched kidneys under present 
circumstances. this group of privileged recipients is needed 
as a baseline for investigations of alternative strategies such 
as CREG matching. 
Although CREG matching is currently being promoted by 
the histocompatibility committee of UNOS. its future role in 
organ transplantation can only be considered speculative. No 
1 , 
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CREG matches were found in recipients of five- to six-HLA-
mismatched kidneys, and a CREG match in a small number 
of cases with two to four HLA mismatches did not confer a 
graft survival advantage. The only encouraging notation was 
that a subset (n=471) of the 1334 one-HLA-mismatched 
UNOS recipients had significantly better survival than their 
863 CREG-mismatched counterparts. It must be empha-
sized, however, that this observation was not confirmed in 
the Pittsburgh analysis, in which exactly the opposite asso-
ciation was seen. In addition, the survival rate of the 81 
Mrican-Americans in the UNOS experience who received 
CREG-matched grafts in the one-HLA mismatch tier was 
inexplicably higher than in the 174 African-American pa-
tients given zero-HLA-mismatched organs, which by defini-
tion (9) were also CREG-matched. 
Whether the approximately one third of the one-HLA-mis-
matched kidneys which are CREG-matched actually have an 
improved prognosis can only be answered by a rigorously 
controlled prospective trial(s). It has been estimated that if 
obligatory sharing were extended to the one-HLA match, 
50% of the national pool of cadaver kidneys exclusive of 
zero-HLA-mismatched cases could be consumed (53). If such 
a policy were enacted, either to enlarge the pool from which 
CREG matches could be extracted or for the statistically 
significant but clinically inconsequential increase in one-
HLA mismatch graft survival seen in the 1991-1995 UNOS 
analysis, only 30% of the organs would be left for allocation 
without an HLA-related ethnic bias. 
Even if a CREG match in one-HLA-mismatched recipients 
were associated with improved graft survival, there is no 
reason to expect correction of the distribution inequity. Our 
UNOS analysis suggests that the rate of distribution of the 
CREG-matched kidneys to African-American recipients 
would be only about half that to the "all other" population. 
Consequently, a CREG matching trial of one-HLA-mis-
matched kidneys, if it is done at all, should be restricted to 
demographically defined local or regional populations in 
which there is a substantial donor as well as recipient Afri-
can-American constituency. Furthermore, such a trial should 
be viewed as a Helsinki Declaration Type I "innovative at-
tempt to treat" or "acquisition of human knowledge" human 
experiment (54), subject to informed consent, frequent spec-
ified analyses, and conditions of trial stoppage. 
Finally, it should be recognized that the polymorphism of 
the human HLA system, as well as the complexities of organ 
transplantation as practiced currently, may preclude im-
provement of matching performance beyond what already 
has been delineated with conventional HLA typing tech-
niques. In bone marrow transplantation, the assumption 
that HLA-A. -B, and -DR were of overriding importance was 
not challenged until recently, in part because HLA-C and 
-DR were not analyzable in related donors because of linkage 
disequilibrium. However. Petersdorf et al. (55,56) have been 
able to show that C and DQ loci are just as important as A. B, 
and DR in determining the outcome after unrelated bone 
marrow transplantation. Whether the effect of these alleles 
would override CREGs in the current organ transplant set-
ting is uncertain. Our preliminary studies (57, 58) have sug-
gested that C and DQ matching would have a more limited 
role than that of the other loci in kidney transplantation. 
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